Ezra M. Friedberg, serving as a director at Pelthos Therapeutics Inc. (NASDAQ:PTHS), has completed a transaction to sell 558 shares of the company's common stock. The sale was executed on July 2, 2026, with the total value of the transaction reaching approximately $14,555. The shares were divested at prices fluctuating between $26.0303 and $27.3254 per share during the execution period.
The disposition of these shares was carried out under the parameters of a Rule 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged stock transactions. Mr. Friedberg originally adopted this specific plan on December 16, 2025. According to the footnote accompanying the official filing, the primary motivation for these sales was to satisfy estimated tax obligations associated with the vesting of restricted stock units that were previously granted to him by Pelthos Therapeutics.
Following the completion of this sale, Mr. Friedberg's direct holdings in Pelthos Therapeutics common stock stand at 81,042 shares. His broader beneficial ownership profile is more complex, extending through corporate entities. He maintains indirect beneficial ownership of 82,072 shares via Balmoral Financial Group LLC and an additional 40,000 shares through Key Recovery Group LLC. As the manager of both Balmoral Financial Group LLC and Key Recovery Group LLC, Mr. Friedberg is considered to beneficially own these shares. However, he has formally disclaimed beneficial ownership over these holdings, except insofar as his pecuniary interest is concerned.
Market performance for Pelthos Therapeutics has exhibited notable weakness following the transaction. PTHS shares have declined to $24.60, representing a drop of roughly 13% over the past week. Despite this recent downward pressure, analysis from InvestingPro suggests the stock may be undervalued, with a calculated Fair Value of $31.93. This valuation gap implies potential upside for investors, even amid the current weakness. The platform's comprehensive Pro Research Report offers deeper insights into the company's financial health and growth prospects for those seeking detailed analysis.
In other corporate developments, Pelthos Therapeutics Inc. reported its Q1 2026 earnings results, which indicated a significant miss on earnings per share (EPS) expectations. The company posted an actual EPS of -3.09 USD, falling short of the forecasted -0.51 USD. This discrepancy marked a surprise of -505.88%. Despite this earnings miss, Pelthos Therapeutics has been added to the Russell 3000E Growth Benchmark, Russell Microcap, and Russell Microcap Growth Benchmark Indexes as of June 29. This inclusion is part of the 2026 Russell indexes reconstitution, which ranks up to the 4,000 largest U.S. stocks by total market capitalization.
Additional insider activity includes a notable stock purchase by director Todd C. Davis, who acquired 35,948 shares for approximately $999,980. This transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission. These developments occur amid a backdrop of investor confidence in Pelthos Therapeutics, driven by strong revenue growth and product performance.